Alzamend Neuro’s AL001 Shows Promise as Next-Generation Lithium Therapy for Neurodegenerative and Neuropsychiatric Conditions
Alzamend Neuro has announced positive results from a phase 2a study of AL001, an investigational lithium-delivery system designed to treat neurodegenerative, neurological, and neuropsychiatric conditions such as Alzheimer’s disease, bipolar disorder, major depressive disorder, and PTSD. The study found a maximum tolerated dose for AL001 that provides the benefits of lithium salts without the associated toxicities. The dose, equivalent to 240 mg of lithium carbonate three times daily, is unlikely to require therapeutic drug monitoring and is considered safe for fragile populations, including Alzheimer’s patients. Alzamend Neuro plans to further evaluate AL001 in two phase 2 clinical trials for Alzheimer’s patients and explore its potential for bipolar disorder, major depressive disorder, and PTSD. They intend to initiate both trials by the first quarter of 2024 and submit investigational new drug applications to the FDA for these indications by the end of 2023. The company believes that AL001 has the potential to revolutionize lithium therapy by providing a next-generation treatment option that improves patient health and safety.